Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Haemonetics Corp (HAE)
Price$102.92Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993.2M | $870.5M | $988.5M | $967.6M | $903.9M | $886.1M | $908.8M | $910.4M | $938.5M | $892.0M | $727.8M | $676.7M | $645.4M | $597.9M |
| Gross profit | $787.6M | $749.0M | $691.5M | $615.1M | $505.5M | $397.8M | $484.5M | $417.5M | $411.9M | $378.5M | $405.9M | $434.4M | $468.4M | $428.1M | $369.2M | $355.2M | $337.5M | $308.2M |
| Gross margin | 59.04% | 55.04% | 52.83% | 52.63% | 50.90% | 45.70% | 49.02% | 43.15% | 45.57% | 42.71% | 44.66% | 47.72% | 49.91% | 48.00% | 50.73% | 52.49% | 52.29% | 51.54% |
| Research & development | $59.8M | $62.7M | $54.4M | $50.1M | $46.8M | $32.9M | $30.9M | $35.7M | $39.2M | $37.6M | $45.0M | $54.2M | $54.2M | $44.4M | $36.8M | $32.7M | $26.4M | $23.9M |
| Operating expenses | $630.9M | $527.1M | $526.7M | $459.1M | $424.8M | $308.1M | $381.2M | $334.0M | $355.8M | $397.9M | $449.9M | $393.9M | $421.9M | $371.7M | $280.5M | $244.7M | $254.2M | $222.6M |
| Operating income | $156.7M | $221.8M | $164.9M | $156.0M | $80.8M | $89.7M | $103.4M | $83.5M | $56.2M | −$19.4M | −$43.9M | $40.5M | $46.4M | $56.4M | $88.8M | $110.5M | $83.3M | $85.6M |
| Operating margin | 11.75% | 16.30% | 12.60% | 13.35% | 8.13% | 10.31% | 10.46% | 8.63% | 6.21% | −2.19% | −4.83% | 4.45% | 4.95% | 6.33% | 12.19% | 16.34% | 12.90% | 14.31% |
| EBITDA | $268.5M | $337.4M | $262.1M | $249.3M | $178.5M | $174.0M | $213.6M | $193.0M | $145.4M | $70.4M | $46.0M | $126.6M | $128.2M | $121.9M | $138.7M | $158.7M | $126.5M | $122.0M |
| EBITDA margin | 20.12% | 24.79% | 20.02% | 21.34% | 17.97% | 19.99% | 21.61% | 19.94% | 16.09% | 7.94% | 5.06% | 13.91% | 13.66% | 13.67% | 19.06% | 23.45% | 19.60% | 20.41% |
| Net income | $97.3M | $167.7M | $117.6M | $115.4M | $43.4M | $79.5M | $76.5M | $55.0M | $45.6M | −$26.3M | −$55.6M | $16.9M | $35.1M | $38.8M | $66.9M | $80.0M | $58.4M | $59.3M |
| Net profit margin | 7.29% | 12.32% | 8.98% | 9.87% | 4.37% | 9.13% | 7.74% | 5.69% | 5.04% | −2.96% | −6.12% | 1.86% | 3.75% | 4.35% | 9.19% | 11.82% | 9.04% | 9.92% |
| Basic EPSper basic share | $2.06 | $3.33 | $2.32 | $2.27 | $0.85 | $1.57 | $1.51 | $1.07 | $0.86 | -$0.51 | -$1.09 | $0.33 | $0.68 | $0.76 | $1.32 | $1.59 | $1.15 | $1.17 |
| Diluted EPSper diluted share | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 | $1.48 | $1.04 | $0.85 | -$0.51 | -$1.09 | $0.32 | $0.67 | $0.74 | $1.30 | $1.56 | $1.12 | $1.14 |
Owners
Reported shareholders
≈13.00%of listed shares
BlackRock, Inc.5.91M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | ≈13.00%5.91M shares |
NEUBERGER BERMAN GROUP LLC | ≈9.19%4.18M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | ≈5.60%2.55M shares |
AQR CAPITAL MANAGEMENT LLC | ≈4.98%2.27M shares |
ARIEL INVESTMENTS, LLC | ≈4.53%2.06M shares |
VANGUARD CAPITAL MANAGEMENT LLC | ≈4.53%2.06M shares |
STATE STREET CORP | ≈4.00%1.82M shares |
DIMENSIONAL FUND ADVISORS LP | ≈3.49%1.59M shares |
CITADEL ADVISORS LLC | ≈3.32%1.51M shares |
GEODE CAPITAL MANAGEMENT, LLC | ≈2.83%1.29M shares |
River Road Asset Management, LLC | ≈2.83%1.29M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ≈2.54%1.16M shares |
T. Rowe Price Investment Management, Inc. | ≈2.42%1.1M shares |
GOLDMAN SACHS GROUP INC | ≈2.30%1.05M shares |
UBS Group AG | ≈2.16%983.38K shares |
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | ≈1.83%830.93K shares |
ROYAL BANK OF CANADA | ≈1.72%780.25K shares |
Allspring Global Investments Holdings, LLC | ≈1.68%765.12K shares |
PRICE T ROWE ASSOCIATES INC /MD/ | ≈1.40%636.8K shares |
DEUTSCHE BANK AG\ | ≈1.39%631.66K shares |
Percentages use 45.47M shares of this listed class outstanding on Jun 27, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 10, 2025Form 4 | KROLL MARK WDirector | BuyCommon Stock | 1.4K | $70.56 | $98.8K | 24.8K |
| Jul 26, 2024Form 4 · 10b5-1 | Strong Stewart WPresident, Global Hospital | SellCommon Stock | 4.3K | $91.15 | $393.0K | 18.2K |
| Jul 12, 2024Form 4 · 10b5-1 | Lingamneni AnilaEVP, Chief Technology Officer | SellCommon Stock | 79 | $90.00 | $7.1K | 21.3K |
| Jul 11, 2024Form 4 · 10b5-1 | Lingamneni AnilaEVP, Chief Technology Officer | SellCommon Stock | 2.1K | $90.00 | $192.2K | 21.4K |